Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Everolimus (0.5mg) Tablet
Therapeutic Category
Immunology, Oncology
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹0/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Everloop 0.5 Tablet contains Everolimus 0.5 mg, a well-established mTOR inhibitor with strong immunosuppressive and antiproliferative properties. It is commonly prescribed for organ transplant patients to prevent graft rejection and for specific oncology indications requiring regulated cell growth control.
Everolimus works by inhibiting the mammalian target of rapamycin (mTOR) pathway, thereby suppressing T-cell activation and abnormal cellular proliferation. This mechanism supports long-term graft survival while helping reduce immune-mediated complications.
Clinically, Everloop 0.5 Tablet is used in renal and other solid organ transplant protocols and in selected cancer therapies, often as part of a carefully monitored treatment regimen to maintain therapeutic balance.
The tablet offers accurate dosing, consistent bioavailability, and dependable clinical performance, making it suitable for hospitals, transplant centers, and specialized oncology care settings where precise immunomodulation is essential.
Common side effects may include mouth ulcers, nausea, diarrhea, fatigue, rash, infections, and increased cholesterol or triglyceride levels. Rare but serious adverse effects include delayed wound healing, lung toxicity, bone marrow suppression, and severe infections.
Everloop 0.5 Tablet is indicated for the prevention of organ transplant rejection when used in combination with other immunosuppressive agents. It is also prescribed for the management of specific malignancies and benign tumors, including renal cell carcinoma, neuroendocrine tumors, and tuberous sclerosis complex–associated conditions, under specialist supervision.
Everloop 0.5 Tablet should be taken strictly as prescribed by a specialist. Regular monitoring of blood counts, renal function, lipid profile, and therapeutic drug levels is recommended. Inform your doctor about any existing infections, liver disorders, or concurrent medications. Avoid live vaccines and report symptoms such as persistent cough, fever, or shortness of breath immediately.
Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children. Do not use after the expiry date.
Composition : Deflazacort (18mg) Tablet
Composition : Deflazacort (30mg)
Composition : Deflazacort (6mg)
Composition : Methylprednisolone (8mg)
Composition : Methylprednisolone (4mg)
Composition : Methylprednisolone (16mg)
Composition : Deflazacort (6mg/5ml)
Composition : Deflazacort (6mg/5ml) Suspension
Composition : Methylprednisolone (1000mg) Injection
Composition : Methylprednisolone (125mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Everolimus 0.5mg Tablet is a specialized immunosuppressant and targeted therapy medicine used in organ transplantation and oncology care, making it a high-value hospital and specialty-care product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in transplant management, oncology departments, and specialty hospitals. It is commonly prescribed by oncologists and transplant specialists for long-term treatment protocols and patient management.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Everolimus 0.5mg Tablet with monopoly rights, specialty-care manufacturing standards, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from stable institutional demand, high-value prescriptions, and long-term therapy cycles in oncology and transplant care when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this specialty-care formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.